Literature DB >> 11280725

Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers.

G L Jiang1, S Huang.   

Abstract

Viral vector-mediated delivery of tumor suppressor genes represents a promising strategy of cancer therapy. Several best-studied tumor suppressor genes, such as p53 and retinoblastoma (Rb), have been evaluated for gene therapy of tumors that carry mutations in these genes. However, these genes may not be applicable to microsatellite instability positive [MSI(+)] tumors because they are rarely mutated in these tumors. The Rb-interacting zinc finger gene RIZ1 is commonly mutated in MSI(+) colorectal, gastric, and endometrial cancers and has demonstrated a capacity to induce cell cycle arrest and apoptosis. Here, we found that RIZ1 expression through adenovirus vectors suppressed growth of MSI(+) HCT116 colorectal xenograft tumors that carry RIZ1 mutations. Malignant cells in the established tumors were efficiently transduced by RIZ1 adenoviruses and underwent apoptosis in response to RIZ1 expression. In comparison, a recombinant p53 adenovirus did not induce apoptosis and tumor suppression. These results suggest that RIZ1 may be useful in gene therapy of MSI(+) colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280725

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Structural and functional characterization of the acidic region from the RIZ tumor suppressor.

Authors:  Yizhi Sun; Jessica M Stine; Daniel Z Atwater; Ayesha Sharmin; J B Alexander Ross; Klára Briknarová
Journal:  Biochemistry       Date:  2015-02-02       Impact factor: 3.162

2.  Synergism between RIZ1 gene therapy and paclitaxel in SiHa cervical cancer cells.

Authors:  H Y Cheng; T Zhang; Y Qu; W J Shi; G Lou; Y X Liu; Y Y Zhang; L Cheng
Journal:  Cancer Gene Ther       Date:  2016-10-07       Impact factor: 5.987

3.  DNA methylation and carcinogenesis of PRDM5 in cervical cancer.

Authors:  Hai-Yan Cheng; Xiu-Wei Chen; Li Cheng; Yun-Duo Liu; Ge Lou
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

4.  Genetic and epigenetic alterations of RIZ1 and the correlation to clinicopathological parameters in liver fluke-related cholangiocarcinoma.

Authors:  Prasong Khaenam; Patcharee Jearanaikoon; Chawalit Pairojkul; Vajarabhongsa Bhudhisawasdi; Temduang Limpaiboon
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

5.  Construction of PR domain eukaryotic expression vector and its inhibitory effect on esophageal cancer cells.

Authors:  Yuan Chen; Peng Zhang; Yuanguo Wang; Shangwen Dong; Yimei Liu
Journal:  Chin J Cancer Res       Date:  2013-10       Impact factor: 5.087

6.  Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily.

Authors:  G Steele-Perkins; W Fang; X H Yang; M Van Gele; T Carling; J Gu; I M Buyse; J A Fletcher; J Liu; R Bronson; R B Chadwick; A de la Chapelle; X Zhang; F Speleman; S Huang
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

7.  Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines.

Authors:  Chenran Zhang; Wei Meng; Jiajia Wang; Yicheng Lu; Guohan Hu; Liuhua Hu; Jie Ma
Journal:  Cell Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.046

8.  Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.

Authors:  Li-Bo Chen; Jun-Yao Xu; Zhen Yang; Guo-Bin Wang
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

Review 9.  Insight to drug delivery aspects for colorectal cancer.

Authors:  Arvind Gulbake; Aviral Jain; Ashish Jain; Ankit Jain; Sanjay K Jain
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  Anticancer activity of the PR domain of tumor suppressor RIZ1.

Authors:  Wanpeng Sun; Ling Qiao; Qiang Liu; Lifeng Chen; Binbing Ling; Ramaswami Sammynaiken; Jian Yang
Journal:  Int J Med Sci       Date:  2011-02-21       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.